<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686618</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01</org_study_id>
    <nct_id>NCT03686618</nct_id>
  </id_info>
  <brief_title>Secretin for Acute Pancreatitis</brief_title>
  <acronym>SNAP</acronym>
  <official_title>A Phase II Study to Establish the Efficacy of Synthetic Human SecretiN in Human Acute Pancreatitis (SNAP) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChiRhoClin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ChiRhoClin, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis is a frequently devastating pancreatic inflammatory process that results
      in extensive morbidity, mortality, and hospitalization costs. The incidence of acute
      pancreatitis has been increasing over the last decade with an overall mortality rate of 5%,
      although it may be as high as 30% in the most severe cases. It was the most common inpatient
      gastrointestinal diagnosis in 2009, totaling over 270,000 hospitalizations with estimated
      &quot;inpatient costs&quot; of over 2.5 billion dollars in the United States. However, despite the
      significant impact to both patients and the healthcare system, there is no proven
      pharmacologic therapy that improves important clinical outcomes in acute pancreatitis. The
      release of bicarbonate rich fluid into the pancreatic duct from the ductal cells is an
      important mechanism to protect against pancreatitis by two distinct mechanisms:

        1. &quot;Flushing&quot; activated enzymes out of the pancreas and into the duodenum thereby
           preventing accumulation of activated enzymes within the pancreatic acinus

        2. Directly alkalinizing the acinar cells, which limits intra-acinar cell damage by
           improving trafficking of inappropriately activated intra-acinar enzymes along the apical
           membrane.

      In addition to standard care, patients will be divided into 4 cohorts. Cohorts 1,2 and 3 will
      be treated with different doses of intravenous synthetic human secretin. Cohort X will not
      receive human secretin, but all datapoints and specimens will be collected. The patient
      cohorts will be entered into the study as follows: Cohort X; Cohort 1; Cohort 2; Cohort 3. 5
      patients in each cohort will be evaluated at each center (for a total of n=10 at both centers
      for each cohort). Dosing will start within 24 hours of hospitalization with no further
      synthetic human secretin administration beyond Day 3. Patients will continue to be followed
      for 7 days or until discharge, whichever comes first. Any data recorded to that point would
      be included in an intent-to-treat analysis. The primary objective is to perform a Phase II
      Pilot Study to explore the efficacy of intravenous synthetic human secretin as a
      pharmacologic adjunct to modulate the severity of human acute (non-obstructive) pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, phase II exploratory pilot study using different dose frequencies of
      intravenous human secretin in patients with non-obstructive, interstitial acute pancreatitis.
      All enrolled patients will receive standard of care therapy in regard to fluid resuscitation,
      pain control, CT scan or ultrasound imaging and nutritional support. In addition to standard
      of care, patients will be divided into 4 cohorts of 10 patients. Cohorts 1,2 and 3 will
      receive different doses of intravenous synthetic human secretin. Cohort X will not receive
      drug. Dosing will start within 24 hours of hospitalization with no further secretin
      administration beyond Day 3. Patients will continue to be followed until discharge. The
      primary study endpoint will be the decrease in serum C-reactive protein (CRP) level by 50%
      within 96 hours and/or at discharge compared with CRP level at admission to determine optimal
      frequency of dosing. Secondary study endpoints will include: 1) Serum measurements of pro-
      and anti-inflammatory cytokines including sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3 ligand,
      Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5,
      IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1,
      MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGF-α, TNF-α, TNF-β, VEGF,
      HSP 27, HSP 60, HSP 70, HSP 90 at time of study enrollment, days of secretin administration,
      96 hours and at discharge 2) Clinically relevant outcome measures including hemoconcentration
      (fall in blood urea nitrogen and hematocrit from admission), decrease in patient admission
      pain scores (visual analogue scale), decrease in systemic inflammatory response, and
      tolerance of oral nutrition 3) Calculation of the Dynamic Acute Pancreatitis Score - organ
      failure, systemic inflammatory response syndrome, abdominal pain, requirement for opiates and
      ability to tolerate oral intake 4) Length of hospitalization, need for intensive care unit
      transfer, mortality, need for surgical, endoscopic or percutaneous intervention 5)
      Development of pancreatic necrosis and/or persistent organ failure and 6) Adverse events and
      30 day readmission rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is not blinded and does not require any randomization codes. Ten patients each will receive one of three treatments for Days 1, 2, and 3:
No secretin - standard of care and observation (Cohort X)
32 mcg (&lt;50kg) or 40 mcg (≥50kg)IV Bolus every 12 hours (Cohort 1)
32 mcg (&lt;50kg) or 40 mcg (≥50kg)IV Bolus every 6 hours (Cohort 2)
32 mcg (&lt;50kg) or 40 mcg (≥50kg)IV Bolus every 4 hours (Cohort 3)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CRP level</measure>
    <time_frame>96 hours and through study completion an average of day 7</time_frame>
    <description>Change in serum C-reactive protein (CRP) level by 50% within 96 hours and/or at discharge compared with CRP level at admission to determine optimal frequency of dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pro- and anti-inflammatory markers</measure>
    <time_frame>Day 1, Day 2, Day 3, 96 hours and through study completion an average of day 7</time_frame>
    <description>Serum measurements of pro- and anti-inflammatory cytokines including sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A,IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGF-α, TNF-α, TNF-β, VEGF, HSP 27, HSP 60, HSP 70, HSP 90 at time of study enrollment, days of secretin administration, 96 hours and at discharge</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Hemoconcentration measurement</measure>
    <time_frame>96 hours and through study completion an average of day 7</time_frame>
    <description>Change in hematocrit from admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hemoconcentration measurements</measure>
    <time_frame>96 hours and through study completion an average of day 7</time_frame>
    <description>Change in blood urea nitrogen from admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute Pancreatitis Activity Score</measure>
    <time_frame>96 hours and through study completion an average of day 7</time_frame>
    <description>A cumulative measurement of the following parameters: (as referenced from the CRF) higher values represent worse outcome Organ Failure (number of systems) x 100 (each system) SIRS (number of criteria) x 25 (each criteria) Abdominal Pain (1-10) x 5 Morphine Equivalent Dose (mg) X 5 Tolerating Solid Diet (yes = 0, no = 1) X 40</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall hospital stay</measure>
    <time_frame>96 hours and through study completion an average of day 7</time_frame>
    <description>Length of hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>30 days following the last administration of study treatment</time_frame>
    <description>Will be reported as a rate per cohort.</description>
  </other_outcome>
  <other_outcome>
    <measure>Readmission Rate</measure>
    <time_frame>30 days following the last administration of study treatment</time_frame>
    <description>Rate will be recorded as number of subjects readmitted within 30 days of final study treatment</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatitis, Acute</condition>
  <arm_group>
    <arm_group_label>Cohort X</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no secretin administered. All observations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 mcg (&lt;50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 mcg (&lt;50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 mcg (&lt;50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secretin</intervention_name>
    <description>Drug to stimulate pancreatic secretion</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>ChiRhoStim®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is male or female ≥18 years of age

          2. Patient voluntarily signed written, informed consent agreement.

          3. If patient is female and not more than 1 year post-menopausal, or surgically sterile,
             must use medically accepted form of contraception or abstain from sexual activities
             during study

          4. Patient has acute pancreatitis as defined by the Atlanta Classification of 2012

          5. No evidence of obstructive pancreatitis on available cross-sectional imaging

        Exclusion Criteria:

          1. Pancreatitis with duct obstruction or severe acute pancreatitis defined by Atlanta
             Classification

          2. Pregnant woman, nursing mothers, or women of childbearing potential not on birth
             control

          3. Known adverse reaction to human secretin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy B Gardner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy B Gardner, MD</last_name>
    <phone>603-650-6472</phone>
    <email>timothy.b.gardner@hitchcock.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Damara Crate, RN</last_name>
    <phone>603-653-9017</phone>
    <email>damara.j.crate@hitchcock.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy B Gardner, M.D.</last_name>
      <phone>603-650-6472</phone>
      <email>timothy.b.gardner@hitchcock.org</email>
    </contact>
    <contact_backup>
      <last_name>Damara Crate, RN</last_name>
      <phone>603-653-9017</phone>
      <email>damara.j.crate@hitchcock.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>National Institutes of Health. Opportunities and challenges in digestive diseases research: recommendations of the national commission on digestive diseases. March 2009. Retrieved January 29, 2017.</citation>
  </reference>
  <reference>
    <citation>Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology. 2009 Apr;136(4):1134-44. doi: 10.1053/j.gastro.2009.02.038. Epub 2009 Feb 24. Review.</citation>
    <PMID>19245868</PMID>
  </reference>
  <reference>
    <citation>Forsmark CE, Vege SS, Wilcox CM. Acute Pancreatitis. N Engl J Med. 2016 Nov 17;375(20):1972-1981. Review.</citation>
    <PMID>27959604</PMID>
  </reference>
  <reference>
    <citation>Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012 Nov;143(5):1179-1187.e3. doi: 10.1053/j.gastro.2012.08.002. Epub 2012 Aug 8.</citation>
    <PMID>22885331</PMID>
  </reference>
  <reference>
    <citation>Lerch MM, Saluja AK, Rünzi M, Dawra R, Saluja M, Steer ML. Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum. Gastroenterology. 1993 Mar;104(3):853-61.</citation>
    <PMID>7680018</PMID>
  </reference>
  <reference>
    <citation>Rattner DW. Experimental models of acute pancreatitis and their relevance to human disease. Scand J Gastroenterol Suppl. 1996;219:6-9.</citation>
    <PMID>8865463</PMID>
  </reference>
  <reference>
    <citation>Hegyi P, Pandol S, Venglovecz V, Rakonczay Z Jr. The acinar-ductal tango in the pathogenesis of acute pancreatitis. Gut. 2011 Apr;60(4):544-52. doi: 10.1136/gut.2010.218461. Epub 2010 Sep 28. Review.</citation>
    <PMID>20876773</PMID>
  </reference>
  <reference>
    <citation>Grady T, Saluja A, Kaiser A, Steer M. Edema and intrapancreatic trypsinogen activation precede glutathione depletion during caerulein pancreatitis. Am J Physiol. 1996 Jul;271(1 Pt 1):G20-6.</citation>
    <PMID>8760102</PMID>
  </reference>
  <reference>
    <citation>Prinz RA. Mechanisms of acute pancreatitis. Vascular etiology. Int J Pancreatol. 1991 Summer;9:31-8. Review.</citation>
    <PMID>1744444</PMID>
  </reference>
  <reference>
    <citation>Hegyi P, Rakonczay Z Jr. The role of pancreatic ducts in the pathogenesis of acute pancreatitis. Pancreatology. 2015 Jul;15(4 Suppl):S13-7. doi: 10.1016/j.pan.2015.03.010. Epub 2015 Apr 7. Review.</citation>
    <PMID>25921231</PMID>
  </reference>
  <reference>
    <citation>Song L, Wörmann S, Ai J, Neuhöfer P, Lesina M, Diakopoulos KN, Ruess D, Treiber M, Witt H, Bassermann F, Halangk W, Steiner JM, Esposito I, Rosendahl J, Schmid RM, Riemann M, Algül H. BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues. Gastroenterology. 2016 Feb;150(2):499-512.e20. doi: 10.1053/j.gastro.2015.10.017. Epub 2015 Oct 23.</citation>
    <PMID>26526716</PMID>
  </reference>
  <reference>
    <citation>Vege SS, Atwal T, Bi Y, Chari ST, Clemens MA, Enders FT. Pentoxifylline Treatment in Severe Acute Pancreatitis: A Pilot, Double-Blind, Placebo-Controlled, Randomized Trial. Gastroenterology. 2015 Aug;149(2):318-20.e3. doi: 10.1053/j.gastro.2015.04.019. Epub 2015 Jun 23.</citation>
    <PMID>26112745</PMID>
  </reference>
  <reference>
    <citation>Noel P, Patel K, Durgampudi C, Trivedi RN, de Oliveira C, Crowell MD, Pannala R, Lee K, Brand R, Chennat J, Slivka A, Papachristou GI, Khalid A, Whitcomb DC, DeLany JP, Cline RA, Acharya C, Jaligama D, Murad FM, Yadav D, Navina S, Singh VP. Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections. Gut. 2016 Jan;65(1):100-11. doi: 10.1136/gutjnl-2014-308043. Epub 2014 Dec 10.</citation>
    <PMID>25500204</PMID>
  </reference>
  <reference>
    <citation>Gardner TB, Vege SS, Pearson RK, Chari ST. Fluid resuscitation in acute pancreatitis. Clin Gastroenterol Hepatol. 2008 Oct;6(10):1070-6. doi: 10.1016/j.cgh.2008.05.005. Epub 2008 Jul 10. Review.</citation>
    <PMID>18619920</PMID>
  </reference>
  <reference>
    <citation>Pitchumoni CS, Agarwal N, Jain NK. Systemic complications of acute pancreatitis. Am J Gastroenterol. 1988 Jun;83(6):597-606. Review.</citation>
    <PMID>3287900</PMID>
  </reference>
  <reference>
    <citation>Chey WY, Chang TM. Secretin: historical perspective and current status. Pancreas. 2014 Mar;43(2):162-82. doi: 10.1097/01.mpa.0000437325.29728.d6. Review.</citation>
    <PMID>24518494</PMID>
  </reference>
  <reference>
    <citation>Chey WY, Chang TM. Secretin, 100 years later. J Gastroenterol. 2003;38(11):1025-35. Review.</citation>
    <PMID>14673718</PMID>
  </reference>
  <reference>
    <citation>Hegyi P, Rakonczay Z. Insufficiency of electrolyte and fluid secretion by pancreatic ductal cells leads to increased patient risk for pancreatitis. Am J Gastroenterol. 2010 Sep;105(9):2119-20. doi: 10.1038/ajg.2010.191.</citation>
    <PMID>20818368</PMID>
  </reference>
  <reference>
    <citation>Takács T, Rosztóczy A, Maléth J, Rakonczay Z Jr, Hegyi P. Intraductal acidosis in acute biliary pancreatitis. Pancreatology. 2013 Jul-Aug;13(4):333-5. doi: 10.1016/j.pan.2013.05.011. Epub 2013 Jun 10.</citation>
    <PMID>23890129</PMID>
  </reference>
  <reference>
    <citation>Hegyi P, Petersen OH. The exocrine pancreas: the acinar-ductal tango in physiology and pathophysiology. Rev Physiol Biochem Pharmacol. 2013;165:1-30. doi: 10.1007/112_2013_14. Review.</citation>
    <PMID>23881310</PMID>
  </reference>
  <reference>
    <citation>Ishiguro H, Naruse S, Kitagawa M, Mabuchi T, Kondo T, Hayakawa T, Case RM, Steward MC. Chloride transport in microperfused interlobular ducts isolated from guinea-pig pancreas. J Physiol. 2002 Feb 15;539(Pt 1):175-89.</citation>
    <PMID>11850511</PMID>
  </reference>
  <reference>
    <citation>Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, Freedman SD, Zielenski J, Berthiaume Y, Corey M, Schibli S, Tullis E, Durie PR. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2011 Jan;140(1):153-61. doi: 10.1053/j.gastro.2010.09.046. Epub 2010 Nov 9.</citation>
    <PMID>20923678</PMID>
  </reference>
  <reference>
    <citation>Freedman SD, Kern HF, Scheele GA. Pancreatic acinar cell dysfunction in CFTR(-/-) mice is associated with impairments in luminal pH and endocytosis. Gastroenterology. 2001 Oct;121(4):950-7.</citation>
    <PMID>11606508</PMID>
  </reference>
  <reference>
    <citation>Behrendorff N, Floetenmeyer M, Schwiening C, Thorn P. Protons released during pancreatic acinar cell secretion acidify the lumen and contribute to pancreatitis in mice. Gastroenterology. 2010 Nov;139(5):1711-20, 1720.e1-5. doi: 10.1053/j.gastro.2010.07.051. Epub 2010 Aug 3.</citation>
    <PMID>20691184</PMID>
  </reference>
  <reference>
    <citation>Hegyi P, Maléth J, Venglovecz V, Rakonczay Z Jr. Pancreatic ductal bicarbonate secretion: challenge of the acinar Acid load. Front Physiol. 2011 Jul 14;2:36. doi: 10.3389/fphys.2011.00036. eCollection 2011.</citation>
    <PMID>21808623</PMID>
  </reference>
  <reference>
    <citation>Goldenberg DE, Gordon SR, Gardner TB. Management of acute pancreatitis. Expert Rev Gastroenterol Hepatol. 2014 Aug;8(6):687-94. doi: 10.1586/17474124.2014.907524. Epub 2014 Apr 25. Review.</citation>
    <PMID>24766182</PMID>
  </reference>
  <reference>
    <citation>Morimoto T, Noguchi Y, Sakai T, Shimbo T, Fukui T. Acute pancreatitis and the role of histamine-2 receptor antagonists: a meta-analysis of randomized controlled trials of cimetidine. Eur J Gastroenterol Hepatol. 2002 Jun;14(6):679-86.</citation>
    <PMID>12072603</PMID>
  </reference>
  <reference>
    <citation>Uhl W, Büchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999 Jul;45(1):97-104.</citation>
    <PMID>10369711</PMID>
  </reference>
  <reference>
    <citation>Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, Lezzi G, Lichino E, Bruno F, Perri F. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther. 1998 Mar;12(3):237-45.</citation>
    <PMID>9570258</PMID>
  </reference>
  <reference>
    <citation>Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, Smith B, Banks PA, Conwell DL. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011 Aug;9(8):710-717.e1. doi: 10.1016/j.cgh.2011.04.026. Epub 2011 May 12.</citation>
    <PMID>21645639</PMID>
  </reference>
  <reference>
    <citation>Levenick JM, Andrews CL, Purich ED, Gordon SR, Gardner TB. A phase II trial of human secretin infusion for refractory type B pain in chronic pancreatitis. Pancreas. 2013 May;42(4):596-600. doi: 10.1097/MPA.0b013e318273f3ec. Erratum in: Pancreas. 2016 May-Jun;45(5):e23. Dosage error in article text.</citation>
    <PMID>23548879</PMID>
  </reference>
  <reference>
    <citation>Stevens T, Conwell DL, Zuccaro G Jr, Van Lente F, Lopez R, Purich E, Fein S. A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. Gastrointest Endosc. 2008 Mar;67(3):458-66. doi: 10.1016/j.gie.2007.07.028.</citation>
    <PMID>18294508</PMID>
  </reference>
  <reference>
    <citation>Conwell DL, Zuccaro G Jr, Vargo JJ, Trolli PA, Vanlente F, Obuchowski N, Dumot JA, O'laughlin C. An endoscopic pancreatic function test with synthetic porcine secretin for the evaluation of chronic abdominal pain and suspected chronic pancreatitis. Gastrointest Endosc. 2003 Jan;57(1):37-40.</citation>
    <PMID>12518128</PMID>
  </reference>
  <reference>
    <citation>Renner IG, Wisner JR Jr. Ceruletide-induced acute pancreatitis in the dog and its amelioration by exogenous secretin. Int J Pancreatol. 1986 May;1(1):39-49.</citation>
    <PMID>3693975</PMID>
  </reference>
  <reference>
    <citation>Renner IG, Wisner JR Jr, Lavigne BC. Partial restoration of pancreatic function by exogenous secretin in rats with ceruletide-induced acute pancreatitis. Dig Dis Sci. 1986 Mar;31(3):305-13.</citation>
    <PMID>2419062</PMID>
  </reference>
  <reference>
    <citation>Niederau C, Ferrell LD, Grendell JH. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin. Gastroenterology. 1985 May;88(5 Pt 1):1192-204.</citation>
    <PMID>2984080</PMID>
  </reference>
  <reference>
    <citation>Evander A, Lundquist I, Ihse I. Influence of gastrointestinal hormones on the course of acute experimental pancreatitis. Hepatogastroenterology. 1982 Aug;29(4):161-6.</citation>
    <PMID>6182081</PMID>
  </reference>
  <reference>
    <citation>Jowell PS, Branch MS, Fein SH, Purich ED, Kilaru R, Robuck G, d'Almada P, Baillie J. Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. Pancreas. 2011 May;40(4):533-9. doi: 10.1097/MPA.0b013e3182152eb6.</citation>
    <PMID>21499206</PMID>
  </reference>
  <reference>
    <citation>Bakker OJ, van Brunschot S, van Santvoort HC, Besselink MG, Bollen TL, Boermeester MA, Dejong CH, van Goor H, Bosscha K, Ahmed Ali U, Bouwense S, van Grevenstein WM, Heisterkamp J, Houdijk AP, Jansen JM, Karsten TM, Manusama ER, Nieuwenhuijs VB, Schaapherder AF, van der Schelling GP, Schwartz MP, Spanier BW, Tan A, Vecht J, Weusten BL, Witteman BJ, Akkermans LM, Bruno MJ, Dijkgraaf MG, van Ramshorst B, Gooszen HG; Dutch Pancreatitis Study Group. Early versus on-demand nasoenteric tube feeding in acute pancreatitis. N Engl J Med. 2014 Nov 20;371(21):1983-93. doi: 10.1056/NEJMoa1404393.</citation>
    <PMID>25409371</PMID>
  </reference>
  <reference>
    <citation>Eatock FC, Chong P, Menezes N, Murray L, McKay CJ, Carter CR, Imrie CW. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. Am J Gastroenterol. 2005 Feb;100(2):432-9.</citation>
    <PMID>15667504</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03686618/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Drug Cohort ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03686618/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Observational Cohort ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03686618/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

